However, the semiconductor segment remains the key, with an increase of 37.4% y-o-y to $79.5 million.
Its analytical life sciences segment did well too, with revenue up 16.7% to $46.6 million.
Despite uncertain geopolitics, Frencken is confident it can weather the current headwinds due to its financial strength, diverse exposure to multiple market segments and entrenched relationships with key customers who are among the market leaders in the high technology industry.
Based on current indicators and barring unforeseen circumstances, Frencken expects its revenue in 1HFY2024 to be comparable to 2HFY2023.
See also: Creative guides for ‘similar level of operating loss’ for 2HFY2025
Frencken shares closed May 14 at $1.36, up 3.03% for the day but down 0.73% year to date.
